BTIG Research Begins Coverage on Renovacor (NYSE:RCOR)

BTIG Research started coverage on shares of Renovacor (NYSE:RCORGet Rating) in a report issued on Wednesday, September 14th, The Fly reports. The firm set a “buy” rating on the stock.

RCOR has been the subject of a number of other research reports. Robert W. Baird started coverage on shares of Renovacor in a research report on Monday, September 12th. They issued an “outperform” rating for the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Renovacor in a research note on Thursday, June 16th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $21.00.

Renovacor Price Performance

Shares of NYSE:RCOR traded down $0.03 on Wednesday, hitting $2.01. The company had a trading volume of 100 shares, compared to its average volume of 131,061. Renovacor has a 1-year low of $1.34 and a 1-year high of $10.47. The stock has a 50 day moving average price of $1.86 and a 200 day moving average price of $2.63.

Institutional Investors Weigh In On Renovacor

An institutional investor recently bought a new position in Renovacor stock. State Street Corp bought a new position in Renovacor, Inc. (NYSE:RCORGet Rating) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,829 shares of the company’s stock, valued at approximately $50,000. State Street Corp owned about 0.07% of Renovacor at the end of the most recent reporting period. Institutional investors and hedge funds own 45.84% of the company’s stock.

Renovacor Company Profile

(Get Rating)

Renovacor, Inc, a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM).

Further Reading

The Fly logo

Analyst Recommendations for Renovacor (NYSE:RCOR)

Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.